Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem - Cardiac LGE

Charité0 个研究点目标入组 40 人开始时间: 2010年1月4日最近更新: 2021年9月7日

适应症

试验速览

暂无简介。

•1.who are female of childbearing potential or in nursery
•2.with moderate impaired renal function (GFR calculated with MDRD formula =60 mL/min/1.72m2). Serum creatinine values must not be older than 12 weeks
•3.with renal transplant, including patients with scheduled renal transplantation
•4.with a contraindication to MRI (e.g. pacemaker, clips, severe claustrophobia)
•5.with known allergy or any contraindication to Gadovist, Magnevist and/or Dotarem
•6.presenting with a history of anaphylactoid or anaphylactic reaction to any of the ingredients of the study drugs.
•7.having any physical or mental status interfering with the informed consent procedure including self-signed informed consent
•8.being unstable or requiring emergency treatment
•9.with close affiliation with the investigational site; e.g. a close relative of the investigator
•10.who have received any contrast agent within 24 hours prior to entering this study
•11.who are scheduled for any therapy between any of the study procedures that may interfere with the comparability of the study procedures
•12.having an underlying disease or concomitant medication which may interfere with efficacy evaluation.
•13.participating in another clinical trial
•14.who have previously entered this study
•15. with severe cardiovascular disease (e.g. congenital or family history of QT syndrome)
•16. who are for legal or regulatory reasons hospitilized in an institution

发起方

Charité